sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.
|
SSRI
|
TCA
|
INT
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s16
|
DDI-DrugBank.d77.s16.p0
|
Median gastric pH was significantly higher when indinavir was taken after didanosine administration;
|
indinavir
|
didanosine
|
MECHANISM
|
11120981.xml
|
DDI-MedLine.d79.s3
|
DDI-MedLine.d79.s3.p0
|
Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation.
|
1,25(OH)2D3
|
TAM
|
EFFECT
|
7654327.xml
|
DDI-MedLine.d53.s5
|
DDI-MedLine.d53.s5.p0
|
In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.
|
enoxacin
|
caffeine
|
MECHANISM
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s3
|
DDI-DrugBank.d395.s3.p0
|
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.
|
vincristine
|
bleomycin
|
NONE
|
11148572.xml
|
DDI-MedLine.d115.s2
|
DDI-MedLine.d115.s2.p25
|
Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
|
dipyridamole
|
heparin sodium
|
EFFECT
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s2
|
DDI-DrugBank.d488.s2.p34
|
Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.
|
VIRACEPT
|
OVCON-35
|
MECHANISM
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s35
|
DDI-DrugBank.d340.s35.p9
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
glucocorticoids
|
sulfonamides
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p405
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
praziquantel
|
topiramate
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p961
|
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
|
Levo-Dromoran
|
anesthetics
|
EFFECT
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s0
|
DDI-DrugBank.d257.s0.p5
|
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
|
propoxyphene
|
salicylates
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s1
|
DDI-DrugBank.d313.s1.p45
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NIMBEX
|
polymyxins
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p19
|
Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.
|
NSAIDs
|
aspirin
|
ADVISE
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s0
|
DDI-DrugBank.d400.s0.p4
|
Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).
|
valdecoxib
|
phenytoin
|
MECHANISM
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s12
|
DDI-DrugBank.d328.s12.p5
|
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
|
Cholestyramine
|
estrogens
|
MECHANISM
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s0
|
DDI-DrugBank.d566.s0.p9
|
Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
|
felbamate
|
Phenytoin
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s8
|
DDI-DrugBank.d94.s8.p32
|
Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a stimulating effect in some depressed patients.
|
reserpine
|
tricyclic antidepressant
|
EFFECT
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s8
|
DDI-DrugBank.d202.s8.p0
|
When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.
|
anesthetics
|
calcium channel blockers
|
ADVISE
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s23
|
DDI-DrugBank.d565.s23.p0
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
tacrolimus
|
ergot alkaloids
|
NONE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p81
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
AKINETON
|
antiarrhythmics
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p14
|
A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
|
miconazole
|
hypoglycemic agents
|
INT
|
Glipizide_ddi.xml
|
DDI-DrugBank.d225.s9
|
DDI-DrugBank.d225.s9.p0
|
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
|
TARCEVA
|
voriconazole
|
ADVISE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s1
|
DDI-DrugBank.d456.s1.p12
|
Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.
|
INDOCIN
|
lithium
|
MECHANISM
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s16
|
DDI-DrugBank.d82.s16.p0
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
VIRACEPT
|
midazolam
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p10
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
ciprofloxacin
|
ciprofloxacin
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p18
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
dextrothyroxine
|
anesthetics
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p714
|
- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);
|
Septra
|
Gantrisin
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s3
|
DDI-DrugBank.d521.s3.p19
|
Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
|
Phenobarbital
|
felbamate
|
NONE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s28
|
DDI-DrugBank.d434.s28.p0
|
These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.
|
contraceptive
|
valdecoxib
|
ADVISE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s46
|
DDI-DrugBank.d328.s46.p5
|
Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.
|
cypermethrin
|
Vitamin E
|
EFFECT
|
11137320.xml
|
DDI-MedLine.d126.s7
|
DDI-MedLine.d126.s7.p1
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
|
norepinephrine
|
tricyclic antidepressants
|
EFFECT
|
Bupivacaine_ddi.xml
|
DDI-DrugBank.d153.s0
|
DDI-DrugBank.d153.s0.p8
|
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.
|
clarithromycin
|
troleandomycin
|
NONE
|
Eszopiclone_ddi.xml
|
DDI-DrugBank.d216.s9
|
DDI-DrugBank.d216.s9.p6
|
Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
|
PRECEDEX
|
hypnotics
|
EFFECT
|
Dexmedetomidine_ddi.xml
|
DDI-DrugBank.d197.s1
|
DDI-DrugBank.d197.s1.p28
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
influenza virus vaccine
|
sulfinpyrazone
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1041
|
Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
|
oxyphenbutazone
|
androgens
|
MECHANISM
|
Dromostanolone_ddi.xml
|
DDI-DrugBank.d129.s2
|
DDI-DrugBank.d129.s2.p0
|
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
|
antidepressants
|
phenothiazines
|
NONE
|
Amitriptyline_ddi.xml
|
DDI-DrugBank.d99.s7
|
DDI-DrugBank.d99.s7.p5
|
In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.
|
diflunisal
|
indomethacin
|
MECHANISM
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s0
|
DDI-DrugBank.d82.s0.p2
|
Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.
|
tricyclic anti-depressants
|
bepridil hydrochloride
|
EFFECT
|
Bepridil_ddi.xml
|
DDI-DrugBank.d137.s10
|
DDI-DrugBank.d137.s10.p2
|
If additional adrenergic drugs are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of BROVANA may be potentiated.
|
adrenergic drugs
|
BROVANA
|
ADVISE
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s0
|
DDI-DrugBank.d284.s0.p0
|
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
terbutaline
|
estrogens
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s2
|
DDI-DrugBank.d313.s2.p81
|
In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.
|
theophylline
|
erythromycin
|
ADVISE
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s1
|
DDI-DrugBank.d397.s1.p5
|
Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
|
nortriptyline
|
combination hormonal contraceptives
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s41
|
DDI-DrugBank.d485.s41.p12
|
Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.
|
Rifampin
|
carvedilol
|
MECHANISM
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s14
|
DDI-DrugBank.d269.s14.p0
|
The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.
|
FLUDARA
|
pentostatin
|
ADVISE
|
Fludarabine_ddi.xml
|
DDI-DrugBank.d444.s0
|
DDI-DrugBank.d444.s0.p0
|
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
|
progestin
|
phenytoin
|
EFFECT
|
Norethindrone_ddi.xml
|
DDI-DrugBank.d306.s0
|
DDI-DrugBank.d306.s0.p1
|
Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
|
PLETAL
|
PLETAL
|
NONE
|
Cilostazol_ddi.xml
|
DDI-DrugBank.d358.s0
|
DDI-DrugBank.d358.s0.p0
|
Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
|
levothyroxine sodium
|
colestipol hydrochloride
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s2
|
DDI-DrugBank.d411.s2.p9
|
Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.
|
nonsteroidal anti-inflammatory drugs
|
ACE inhibitors
|
INT
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s7
|
DDI-DrugBank.d172.s7.p2
|
Effect of Sensipar on other drugs: Drugs metabolized by cytochrome P450 2D6 (CYP2D6): Sensipar is a strong in vitro inhibitor of CYP2D6.
|
Sensipar
|
Sensipar
|
NONE
|
Cinacalcet_ddi.xml
|
DDI-DrugBank.d512.s1
|
DDI-DrugBank.d512.s1.p0
|
- Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.
|
Antihypertensives
|
Bumetanide
|
NONE
|
Bumetanide_ddi.xml
|
DDI-DrugBank.d331.s9
|
DDI-DrugBank.d331.s9.p0
|
Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine.
|
norepinephrine
|
desipramine
|
NONE
|
7798493.xml
|
DDI-MedLine.d94.s17
|
DDI-MedLine.d94.s17.p1
|
Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
|
butorphanol
|
antihistamines
|
EFFECT
|
Butorphanol_ddi.xml
|
DDI-DrugBank.d246.s0
|
DDI-DrugBank.d246.s0.p4
|
Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
|
aluminum
|
calcium
|
NONE
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s1
|
DDI-DrugBank.d78.s1.p24
|
Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor.
|
escitalopram
|
non-selective MAO inhibitor
|
ADVISE
|
Fluoxetine_ddi.xml
|
DDI-DrugBank.d482.s9
|
DDI-DrugBank.d482.s9.p0
|
Concurrent use of flurbiprofen and aspirin is therefore not recommended.
|
flurbiprofen
|
aspirin
|
ADVISE
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s6
|
DDI-DrugBank.d529.s6.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
ibuprofen
|
sulfamethoxazole
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p987
|
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
|
Tagamet
|
warfarin-type anticoagulants
|
MECHANISM
|
Cimetidine_ddi.xml
|
DDI-DrugBank.d171.s0
|
DDI-DrugBank.d171.s0.p0
|
Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;
|
Sensipar
|
ketoconazole
|
ADVISE
|
Cinacalcet_ddi.xml
|
DDI-DrugBank.d512.s7
|
DDI-DrugBank.d512.s7.p0
|
Aminoglutethimide diminishes the effect of coumarin and warfarin.
|
Aminoglutethimide
|
coumarin
|
EFFECT
|
Aminoglutethimide_ddi.xml
|
DDI-DrugBank.d372.s2
|
DDI-DrugBank.d372.s2.p0
|
Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.
|
TRICOR
|
pravastatin
|
MECHANISM
|
Fenofibrate_ddi.xml
|
DDI-DrugBank.d283.s13
|
DDI-DrugBank.d283.s13.p3
|
The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
|
antipsychotic drug
|
tricyclic antidepressant
|
EFFECT
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s0
|
DDI-DrugBank.d86.s0.p3
|
This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.
|
probenecid
|
cloxacillin
|
MECHANISM
|
15830476.xml
|
DDI-MedLine.d29.s8
|
DDI-MedLine.d29.s8.p0
|
At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin.
|
atracurium
|
gentamycin
|
EFFECT
|
8542840.xml
|
DDI-MedLine.d90.s9
|
DDI-MedLine.d90.s9.p2
|
Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
|
ketoconazole
|
aripiprazole
|
MECHANISM
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s8
|
DDI-DrugBank.d509.s8.p3
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
sodium colistimethate
|
lithium
|
NONE
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p91
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Agenerase
|
rifampin
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p814
|
Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates).
|
alosetron
|
levonorgestrel
|
NONE
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s17
|
DDI-DrugBank.d364.s17.p2
|
When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.
|
carbamazepine
|
aripiprazole
|
ADVISE
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s20
|
DDI-DrugBank.d509.s20.p0
|
Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.
|
NIMBEX
|
NIMBEX
|
NONE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s8
|
DDI-DrugBank.d60.s8.p5
|
Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
|
digoxin
|
nifedipine
|
ADVISE
|
Nifedipine_ddi.xml
|
DDI-DrugBank.d373.s7
|
DDI-DrugBank.d373.s7.p2
|
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.
|
3H-spiroperidol
|
apomorphine
|
NONE
|
2857100.xml
|
DDI-MedLine.d15.s0
|
DDI-MedLine.d15.s0.p14
|
Concurrent therapy with ORENCIA and TNF antagonists is not recommended.
|
ORENCIA
|
TNF antagonists
|
ADVISE
|
Abatacept_ddi.xml
|
DDI-DrugBank.d297.s4
|
DDI-DrugBank.d297.s4.p0
|
Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
|
organophosphate insecticide
|
carbamate insecticide
|
NONE
|
Echothiophate Iodide_ddi.xml
|
DDI-DrugBank.d377.s0
|
DDI-DrugBank.d377.s0.p9
|
Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.
|
valdecoxib
|
omeprazole
|
MECHANISM
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s39
|
DDI-DrugBank.d328.s39.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
antibiotics
|
fenoprofen
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p322
|
Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
|
clozapine
|
propafenone
|
ADVISE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s30
|
DDI-DrugBank.d480.s30.p4
|
Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).
|
Cimetidine
|
dofetilide
|
MECHANISM
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s3
|
DDI-DrugBank.d558.s3.p0
|
SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.
|
SUBOXONE
|
benzodiazepines
|
ADVISE
|
Buprenorphine_ddi.xml
|
DDI-DrugBank.d380.s6
|
DDI-DrugBank.d380.s6.p2
|
Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
|
Anafranil
|
warfarin
|
MECHANISM
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s24
|
DDI-DrugBank.d238.s24.p3
|
Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.
|
Acarbose
|
digoxin
|
MECHANISM
|
Acarbose_ddi.xml
|
DDI-DrugBank.d536.s5
|
DDI-DrugBank.d536.s5.p0
|
The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis.
|
macrolide antibiotics
|
hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
|
EFFECT
|
11197581.xml
|
DDI-MedLine.d25.s10
|
DDI-MedLine.d25.s10.p0
|
Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
|
Codeine
|
narcotic analgesics
|
EFFECT
|
Codeine_ddi.xml
|
DDI-DrugBank.d464.s0
|
DDI-DrugBank.d464.s0.p0
|
Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
|
Uricosuric drugs
|
nitrofurantoin
|
MECHANISM
|
Nitrofurantoin_ddi.xml
|
DDI-DrugBank.d276.s2
|
DDI-DrugBank.d276.s2.p2
|
- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
|
Cataflam
|
etodolac
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s2
|
DDI-DrugBank.d521.s2.p222
|
Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.
|
cephalexin
|
metformin
|
MECHANISM
|
Cephalexin_ddi.xml
|
DDI-DrugBank.d303.s0
|
DDI-DrugBank.d303.s0.p4
|
Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
|
ketoconazole
|
gefitinib
|
MECHANISM
|
Gefitinib_ddi.xml
|
DDI-DrugBank.d207.s4
|
DDI-DrugBank.d207.s4.p2
|
In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.
|
gentamicin
|
EXTRANEAL
|
NONE
|
Icodextrin_ddi.xml
|
DDI-DrugBank.d501.s10
|
DDI-DrugBank.d501.s10.p32
|
Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
|
ciprofloxacin
|
calcium
|
NONE
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s8
|
DDI-DrugBank.d43.s8.p16
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
cholestyramine
|
ethchlorvynol
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p173
|
Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.
|
flurbiprofen
|
cimetidine
|
MECHANISM
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s12
|
DDI-DrugBank.d529.s12.p20
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NUROMAX
|
sodium colistimethate
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p8
|
However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
|
clozapine
|
sertraline
|
MECHANISM
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s22
|
DDI-DrugBank.d480.s22.p6
|
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
|
VISTIDE
|
gentamicin
|
ADVISE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s3
|
DDI-DrugBank.d260.s3.p2
|
A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.
|
nisoldipine
|
cimetidine 400 mg
|
MECHANISM
|
Nisoldipine_ddi.xml
|
DDI-DrugBank.d106.s0
|
DDI-DrugBank.d106.s0.p0
|
Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.
|
anticoagulants
|
chlordiazepoxide
|
EFFECT
|
Chlordiazepoxide_ddi.xml
|
DDI-DrugBank.d336.s0
|
DDI-DrugBank.d336.s0.p0
|
Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
|
hormonal contraceptives
|
temazepam
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s17
|
DDI-DrugBank.d485.s17.p14
|
Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
|
Tegretol
|
estrogens
|
NONE
|
Fluoxetine_ddi.xml
|
DDI-DrugBank.d482.s14
|
DDI-DrugBank.d482.s14.p89
|
Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
|
Barbiturates
|
doxycycline
|
MECHANISM
|
Doxycycline_ddi.xml
|
DDI-DrugBank.d500.s4
|
DDI-DrugBank.d500.s4.p2
|
Enhanced theophylline clearance secondary to phenytoin therapy.
|
theophylline
|
phenytoin
|
MECHANISM
|
3967572.xml
|
DDI-MedLine.d7.s0
|
DDI-MedLine.d7.s0.p0
|
These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde;
|
ethanol
|
acetaldehyde
|
EFFECT
|
7653281.xml
|
DDI-MedLine.d107.s9
|
DDI-MedLine.d107.s9.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.